Physician profile
David Robert Crotzer
NPI 1578514956
$70,174.48
in general payments reported to CMS, 2019-2025
25 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $20K · 2022: $372 · 2023: $9,668 · 2024: $682 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,350 · Food and Beverage: $1,279 · Travel and Lodging: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,350.00 |
| Food and Beverage | $1,278.64 |
| Travel and Lodging | $975.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66,103.11 | 2019-2024 | Lynparza |
| Genentech, INC. | $2,200.00 | 2020 | |
| Eisai INC. | $290.31 | 2020-2024 | |
| Glaxosmithkline, LLC. | $261.00 | 2020-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $255.74 | 2020-2025 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $189.42 | 2020-2024 | Myrisk, Mychoice Cdx |
| Clovis Oncology, INC. | $125.43 | 2019-2021 | |
| Pfizer INC. | $97.67 | 2024 | |
| Baxter Healthcare | $90.62 | 2019 | |
| Genentech USA, INC. | $89.03 | 2019 | |
| Fennec Pharmaceuticals, INC. | $72.73 | 2025 | Fyarro |
| Seagen INC. | $61.79 | 2022-2023 | Tivdak |
| Abbvie INC. | $49.04 | 2025 | |
| Conmed Corporation | $47.05 | 2025 | Airseal |
| Amgen INC. | $43.53 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $28.00 | 2024 | Celleraterx |
| Daiichi Sankyo INC. | $26.93 | 2025 | Enhertu |
| Mallinckrodt Enterprises LLC | $26.20 | 2019 | |
| Olympus America INC. | $24.46 | 2019 | |
| Kyowa Kirin, INC. | $22.87 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.57 | 2020 | |
| Tesaro, INC. | $19.62 | 2019 | |
| Integra Lifesciences Corporation | $15.23 | 2024 | Codman Certas, Codman Hakim, Cusa Clarity |
| Astellas Pharma US INC | $14.13 | 2023 | Veozah |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$360,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crotzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.